- Recruiting
NCT05016778: Phase 1: (OriCAR-017) - CAR-T Cells Targeting GPRC5D in the Treatment of RRMM - POLARIS
Updated: Sep 29, 2022
(OriCAR-017)
CAR-T Cells Targeting GPRC5D in the Treatment of Relapsed / Refractory Multiple Myeloma (POLARIS)

NCT05016778: Phase 1: A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma
A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma
This is a single-arm, open-label, dose-escalation study to evaluate the safety, tolerability, cellular kinetics and initial efficacy of CAR-T cell therapy targeting GPRC5D in multiple myeloma subjects who have failed the standard treatments.
Sponsor:
Zhejiang University
Collaborator:
Location:
China, Zhejiang
The first affiliated hospital of medical college of zhejiang university
Hangzhou, Zhejiang, China, 310003
ClinicalTrials.gov Identifier: NCT05016778
Official Title: A Single Arm, Open Label Clinical Study of CAR-T Cells Targeting GPRC5D in the Treatment of Relapsed / Refractory Multiple Myeloma (POLARIS)
First Posted: August 23, 2021
Click here to see details on ClinicalTrials.gov
Drug: GPRC5D-CAR-T